


PRESS RELEASE

Metropolis Healthcare maintains Growth Momentum; Revenue Rises 23% YoY to ₹429 Crore, EBITDA grows by 19%.

Mumbai, India, 4th November 2025: Ameera Shah-led [Metropolis Healthcare Limited](#) (NSE: METROPOLIS | BSE: 542650), India’s second-largest and most trusted pathology laboratory chain, today announced its unaudited consolidated financial results for the quarter ended September 30, 2025 (Q2FY26).



Key Financial & Operational Highlights – Q2FY26

- **Patient and Test Volumes** grew 11% and 12% YoY, respectively, with **B2C and B2B revenues** rising 16% and 33% YoY.
- **Revenue per Patient (RPP) and Revenue per Test (RPT)** increased 11% and 10% YoY, supported by brand trust, premium offerings, and rising demand for preventive and specialty testing.
- **TruHealth wellness** and **Specialty** portfolios recorded strong growth of ~24% and ~33% YoY growth respectively, underscoring momentum in high-value services.
- **North India’s revenue contribution** rose to 19% (from 17% in Q1FY26), while **Tier III cities** registered 13% revenue growth.
- **Core Diagnostics** PAT is positive within two quarters of acquisition, achieving high single-digit EBITDA margins in Q2; **DAPIC (Dehradun)** and **Scientific Pathology (Agra)** continue to outperform the company’s average margin levels.
- **The Board has approved a dividend of 200% (₹4 per share).**

“We’ve demonstrated that consistent growth and quality can go hand in hand. The swift turnaround of Core Diagnostics and the strong performance of our recent acquisitions in Dehradun and Agra reaffirm the strength of our integration strategy and our ability to create sustainable value through local excellence. As we advance genomics and AI-enabled innovation alongside digital transformation, we’re driving rapid adoption that expands access to quality diagnostics and accelerates the sector’s shift from unorganised to organised players. Our focus remains on shaping a future-ready Metropolis — a trusted, science-led organisation that sets new benchmarks for quality, care, and value creation.”
~ Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited.

“We delivered consistent results this quarter, in line with our guidance, even as lower incidence of vector-borne diseases impacted seasonal demand. Our focus on execution excellence, productivity enhancement, and operational optimisation helped sustain growth momentum and deliver year-on-



year margin expansion in H1. We continue to deepen our presence across the 750+ towns we serve, with sharper penetration in Tier 2 and Tier 3 markets, supported by a strong product portfolio and productivity-enhancing initiatives in the network. We remain confident of achieving our stated growth and profitability targets for the rest of the year." ~ Surendran Chemmenkotil, Managing Director, Metropolis Healthcare Limited.

About Metropolis Healthcare Limited: Established in 1981, Metropolis Healthcare Limited is India’s second-largest diagnostic chain, led by visionary leader Ms. Ameera Shah. With over four decades of excellence, Metropolis has been a pioneer in delivering best-in-class diagnostic services to patients, healthcare providers, and corporates across India and Africa. The company’s extensive footprint spans 28 states, 7 Union Territories, and over 750+ towns in India, supported by a robust network of more than 221 laboratories, ~ 4,600 plus patient service centers, and over 10,000 touchpoints. Each year, Metropolis serves millions of individuals by providing actionable health insights that empower better clinical outcomes.

Metropolis offers a comprehensive range of more than 4,100 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. The company’s commitment to quality and accuracy is reinforced by its consistent CAP proficiency score of over 99% for the past decade, placing it among the top 1% of laboratories worldwide for quality assurance. The Metropolis philosophy is built on the pillars of technological superiority, a warm, patient-centric approach, and reliable diagnostic reports. For more information, please visit www.metropolisindia.com or click on [Twitter](#), [Facebook](#), or [LinkedIn](#)

Safe harbor statement: Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

<p>Company: Metropolis Healthcare Ltd. CIN -L73100MH2000PLC192798 Mr. Jeyasingh Balakrishnan Head - Corporate Communications jeyasingh.b@metropolisindia.com</p>	<p>Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd. CIN: U74140MH2010PTC204285 Mr. Shogun Jain / Mr. Sagar Shroff +91 77383 77756 / +91 98205 19303 shogun.jain@sgapl.net / sagar.shroff@sgapl.net</p>
--	--